Literature DB >> 20693544

Morbidity and mortality in heart failure patients treated with cardiac resynchronization therapy: influence of pre-implantation characteristics on long-term outcome.

Rutger J van Bommel1, Carel Jan Willem Borleffs, Claudia Ypenburg, Nina Ajmone Marsan, Victoria Delgado, Matteo Bertini, Ernst E van der Wall, Martin J Schalij, Jeroen J Bax.   

Abstract

AIMS: Cardiac resynchronization therapy (CRT) improves cardiac function, heart failure symptoms, and prognosis in selected patients. Many baseline characteristics associated with heart failure may influence prognosis after CRT. The objective of this study was to evaluate the effect of several baseline characteristics in relation to long-term prognosis in heart failure patients treated with CRT. METHODS AND
RESULTS: A total of 716 consecutive heart failure patients treated with CRT were included in an observational registry. All available data, including clinical and echocardiographic measurements, were analysed in relation to two endpoints: all-cause mortality and a combined endpoint of all-cause mortality or major cardiovascular event. Outcome data were collected by chart review, device interrogation, and telephone contact. Mean follow-up was 25 ± 19 months. During follow-up, 141 patients (20%) died (primary endpoint). Most of these patients (61%) died due to worsening heart failure. A total of 214 patients (30%) reached the secondary endpoint. Larger left ventricular end-systolic volume, less distance covered in the 6 min walking test, poor renal function, more severe heart failure, male gender, presence of atrial fibrillation, no posterolateral left ventricular (LV) lead, and no LV dyssynchrony were associated with poor prognosis after CRT.
CONCLUSION: In this large single-centre registry, several baseline clinical and echocardiographic characteristics were associated with prognosis after CRT. Worsening heart failure was the main cause of death in heart failure patients treated with CRT.

Entities:  

Mesh:

Year:  2010        PMID: 20693544     DOI: 10.1093/eurheartj/ehq252

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  20 in total

1.  Effect of cardiac resynchronization therapy in patients without left intraventricular dyssynchrony.

Authors:  Dominique Auger; Gabe B Bleeker; Matteo Bertini; See H Ewe; Rutger J van Bommel; Tomasz G Witkowski; Arnold C T Ng; Lieselot van Erven; Martin J Schalij; Jeroen J Bax; Victoria Delgado
Journal:  Eur Heart J       Date:  2012-01-24       Impact factor: 29.983

2.  Machine Learning Algorithm Predicts Cardiac Resynchronization Therapy Outcomes: Lessons From the COMPANION Trial.

Authors:  Matthew M Kalscheur; Ryan T Kipp; Matthew C Tattersall; Chaoqun Mei; Kevin A Buhr; David L DeMets; Michael E Field; Lee L Eckhardt; C David Page
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-01

Review 3.  Sex differences in device therapy for heart failure: utilization, outcomes, and adverse events.

Authors:  Naomi D Herz; Joseph Engeda; Robbert Zusterzeel; William E Sanders; Kathryn M O'Callaghan; David G Strauss; Samantha B Jacobs; Kimberly A Selzman; Ileana L Piña; Daniel A Caños
Journal:  J Womens Health (Larchmt)       Date:  2015-03-20       Impact factor: 2.681

4.  Predictors of mortality, LVAD implant, or heart transplant in primary prevention cardiac resynchronization therapy recipients: The HF-CRT score.

Authors:  Victor Nauffal; Tanyanan Tanawuttiwat; Yiyi Zhang; John Rickard; Joseph E Marine; Barbara Butcher; Sanaz Norgard; Timm Dickfeld; Kenneth A Ellenbogen; Eliseo Guallar; Gordon F Tomaselli; Alan Cheng
Journal:  Heart Rhythm       Date:  2015-07-17       Impact factor: 6.343

5.  Combined management of atrial fibrillation and heart failure: case studies.

Authors:  Frederik H Verbrugge; Wilfried Mullens
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

6.  Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.

Authors:  Giuseppe Boriani; Irina Savelieva; Gheorghe-Andrei Dan; Jean Claude Deharo; Charles Ferro; Carsten W Israel; Deirdre A Lane; Gaetano La Manna; Joseph Morton; Angel Moya Mitjans; Marc A Vos; Mintu P Turakhia; Gregory Y H Lip
Journal:  Europace       Date:  2015-06-24       Impact factor: 5.214

7.  Validation of Three European Risk Scores to Predict Long-Term Outcomes for Patients Receiving Cardiac Resynchronization Therapy in an Asian Population.

Authors:  Shengwen Yang; Zhimin Liu; Wenran Li; Yiran Hu; Shangyu Liu; Ran Jing; Wei Hua
Journal:  J Cardiovasc Transl Res       Date:  2020-05-05       Impact factor: 4.132

8.  Clinical implication of mechanical dyssynchrony in heart failure.

Authors:  Qing Zhang; Cheuk-Man Yu
Journal:  J Cardiovasc Ultrasound       Date:  2012-09-21

9.  Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy.

Authors:  Ulas Höke; Joep Thijssen; Rutger J van Bommel; Lieselot van Erven; Enno T van der Velde; Eduard R Holman; Martin J Schalij; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Diabetes Care       Date:  2012-12-05       Impact factor: 19.112

10.  Predictive factors and clinical effect of optimized cardiac resynchronization therapy.

Authors:  Guo-Jun Xu; Tian-Yi Gan; Bao-Peng Tang; Yi-Tong Ma; Yu Zhang; Jin-Xin Li; Yan-Yi Zhang; Jiang Wang; Qi Tang; Chun-Mei Wang; Yao-Dong Li; Jiang-Hua Zhang
Journal:  Exp Ther Med       Date:  2012-06-11       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.